Literature DB >> 14982509

Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation.

M Kurowski1, P Kuna, P Górski.   

Abstract

BACKGROUND: The aim of our study was to investigate effects of 6-week pretreatment of seasonal allergic rhinitis (AR) with cetirizine, and montelukast, alone and in combination. Antihistamine/antileukotriene treatment is effective in AR. Antihistamines may prevent AR symptoms while prophylactic activity of antileukotrienes remains unclear.
METHODS: Sixty AR patients, aged 18-35 years, were randomized to receive placebo, montelukast only, cetirizine only, or montelukast plus cetirizine, 6 weeks prior and 6 weeks after the beginning of grass pollen season. Mean self-recorded in-season symptom scores and mean weekly all-symptom scores were analyzed. In 31 patients, nasal lavages were performed before treatment, and at the end of the study, i.e. 12 weeks after the treatment initiation. Eosinophil and basophil counts, eosinophil cationic protein (ECP), and mast cell tryptase (MCT) levels were evaluated in lavage samples.
RESULTS: Combined montelukast/cetirizine pretreatment significantly reduced in-season symptom score for sneezing, eye itching, nasal itching, rhinorrhea, and congestion. Montelukast plus cetirizine were more effective than cetirizine alone in preventing eye itching, rhinorrhea, and nasal itching. Moreover, combined pretreatment with montelukast and cetirizine delayed appearance of AR symptoms. Eosinophil nasal lavage fluid counts were significantly increased during pollen season in placebo and montelukast-only groups. No differences were observed in basophil counts. The in-season ECP level was significantly increased in all groups except montelukast-plus-cetirizine group. In-season MCT levels were not increased.
CONCLUSION: Combined antihistamine and antileukotriene treatment started 6 weeks before the pollen season is effective in preventing AR symptoms and reduces allergic inflammation in nasal mucosa during natural allergen exposure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14982509     DOI: 10.1046/j.1398-9995.2003.00416.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  14 in total

Review 1.  Hay fever in adolescents and adults.

Authors:  Aziz Sheikh; Sukhmeet Singh Panesar; Sarah Salvilla; Sangeeta Dhami
Journal:  BMJ Clin Evid       Date:  2009-11-18

2.  Cost-effectiveness of second-generation antihistamines and montelukast in relieving allergic rhinitis nasal symptoms.

Authors:  Michael J Goodman; Mehul Jhaveri; Kim Saverno; Kellie Meyer; Brian Nightengale
Journal:  Am Health Drug Benefits       Date:  2008-10

Review 3.  Role of leukotriene antagonists and antihistamines in the treatment of allergic rhinitis.

Authors:  Bengü Cobanoğlu; Elina Toskala; Ahmet Ural; Cemal Cingi
Journal:  Curr Allergy Asthma Rep       Date:  2013-04       Impact factor: 4.806

4.  The pathophysiology, diagnosis and treatment of allergic rhinitis.

Authors:  Yang-Gi Min
Journal:  Allergy Asthma Immunol Res       Date:  2010-03-24       Impact factor: 5.764

Review 5.  Histamine and leukotriene receptor antagonism in the treatment of allergic rhinitis: an update.

Authors:  Helen Van Hoecke; Liesbet Vandenbulcke; Paul Van Cauwenberge
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  The role of antileukotriene drugs in management of rhinitis and rhinosinusitis.

Authors:  Mitchell H Grayson; Phillip E Korenblat
Journal:  Curr Allergy Asthma Rep       Date:  2007-06       Impact factor: 4.806

Review 7.  Montelukast in the treatment of allergic rhinitis: an evidence-based review.

Authors:  Anjuli Nayak; Ronald B Langdon
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis.

Authors:  M Peters-Golden; M M Gleason; A Togias
Journal:  Clin Exp Allergy       Date:  2006-06       Impact factor: 5.018

9.  HPTLC-Densitometric Determination of Cetirizine and Montelukast Analysis in Combined Tablet Dosage Forms.

Authors:  Saeed Haghighi; Mahmoud Reza Shapouri; Mitra Amoli-Diva; Kamyar Pourghazi; Hossein Afruzi
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

10.  Montelukast in the management of allergic rhinitis.

Authors:  Jaime A Lagos; Gailen D Marshall
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.